Prescriptions dispensed for apixaban beyond 90 days after hospitalization resulted in a lower rate of hospitalization for recurrent venous thromboembolism compared with warfarin beyond 90 days, according to study results published in JAMA.
However, researchers observed no significant differences in risk for hospitalization for major bleeds and no significant differences for comparisons between apixaban vs. rivaroxaban and rivaroxaban vs. warfarin.
“Guidelines for managing VTE recommend at least 90 days of therapy with oral anticoagulants. Limited evidence exists about the optimal drug for